GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arno Therapeutics Inc (OTCPK:ARNI) » Definitions » Days Sales Outstanding

Arno Therapeutics (Arno Therapeutics) Days Sales Outstanding : 0.00 (As of Sep. 2016)


View and export this data going back to 2006. Start your Free Trial

What is Arno Therapeutics Days Sales Outstanding?

Arno Therapeutics's average Accounts Receivable for the three months ended in Sep. 2016 was $0.00 Mil. Arno Therapeutics's Revenue for the three months ended in Sep. 2016 was $0.00 Mil.

The historical rank and industry rank for Arno Therapeutics's Days Sales Outstanding or its related term are showing as below:

ARNI's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 72.665
* Ranked among companies with meaningful Days Sales Outstanding only.

Arno Therapeutics's Days Sales Outstanding stayed the same from Sep. 2015 (0.00) to Sep. 2016 (0.00).


Arno Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Arno Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arno Therapeutics Days Sales Outstanding Chart

Arno Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arno Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arno Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Arno Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arno Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arno Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Arno Therapeutics's Days Sales Outstanding falls into.



Arno Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Arno Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2015 is calculated as

Days Sales Outstanding (A: Dec. 2015 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2014 ) + Accounts Receivable (A: Dec. 2015 )) / count ) / Revenue (A: Dec. 2015 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Arno Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2016 is calculated as:

Days Sales Outstanding (Q: Sep. 2016 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2016 ) + Accounts Receivable (A: Sep. 2016 )) / count ) / Revenue (A: Sep. 2016 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arno Therapeutics  (OTCPK:ARNI) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Arno Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Arno Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Arno Therapeutics (Arno Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.
Executives
S Donald Sussman other: See Footnote 1 888 EAST LAS OLAS BLVD, SUITE 710, FORT LAUDERDALE FL 33301
David M Tanen director, officer: Secretary TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Arie Belldegrun director UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Alexander A Zukiwski director, officer: Chief Executive Officer & CMO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Jay Moorin director C/O PROQUEST INVESTMENTS, L.P, 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Lawrence A Kenyon officer: Chief Financial Officer C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Glenn R. Mattes director, officer: President & CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Wexford Gp Llc other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Joseph Jacobs other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Capital Lp other: No longer own 10% of Issuer 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Charles E Davidson other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Ran Nussbaum 10 percent owner C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Brian Lenz officer: Chief Financial Officer 65 COMMERCE WAY, HACKENSACK NJ 07601

Arno Therapeutics (Arno Therapeutics) Headlines

No Headlines